MannKind Corporation (MNKD) Research

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Market snapshot

Symbol
MNKD
Price
$3.94
Day change
+0.51%
Market cap
$1.2B
P/E ratio
-50.79x
52-week range
2.23-6.51
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$8.50

Recent news

  • US FDA approves MannKind's inhaled insulin for children

    The U.S. Food and Drug Administration has approved expanded use ​of MannKind's inhaled rapid-acting insulin ‌in children with diabetes, offering patients under 18 years of age a ​needle-free treatment option, the ​company said on Friday.

Peer companies

  • AbCellera Biologics Inc. (ABCL)
  • Aurinia Pharmaceuticals Inc. (AUPH)
  • Biohaven Ltd. (BHVN)
  • Celldex Therapeutics, Inc. (CLDX)
  • Harmony Biosciences Holdings, Inc. (HRMY)
  • Immunocore Holdings plc (IMCR)
  • Janux Therapeutics, Inc. (JANX)
  • Nuvation Bio Inc. (NUVB)

Recent insider activity

  • Friedman Michael A — A-Award (82781 shares) on 2026-05-20
  • Consiglio Ronald J — A-Award (10000 shares) on 2026-05-20
  • Consiglio Ronald J — A-Award (82781 shares) on 2026-05-20
  • Consiglio Ronald J — A-Award (16556 shares) on 2026-05-20
  • Binder Steven B. — A-Award (82781 shares) on 2026-05-20

Open MannKind Corporation (MNKD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.